373 related articles for article (PubMed ID: 24182857)
21. Urinary neutrophil gelatinase-associated lipocalin for diagnosis and estimating activity in lupus nephritis: a meta-analysis.
Fang YG; Chen NN; Cheng YB; Sun SJ; Li HX; Sun F; Xiang Y
Lupus; 2015 Dec; 24(14):1529-39. PubMed ID: 26314302
[TBL] [Abstract][Full Text] [Related]
22. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis.
Malvar A; Alberton V; Lococo B; Ferrari M; Delgado P; Nagaraja HN; Rovin BH
Kidney Int; 2020 Jan; 97(1):156-162. PubMed ID: 31685314
[TBL] [Abstract][Full Text] [Related]
23. Systemic lupus erythematosus biomarkers: the challenging quest.
Arriens C; Wren JD; Munroe ME; Mohan C
Rheumatology (Oxford); 2017 Apr; 56(suppl_1):i32-i45. PubMed ID: 28013203
[TBL] [Abstract][Full Text] [Related]
24. Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults.
Brunner HI; Bennett MR; Gulati G; Abulaban K; Klein-Gitelman MS; Ardoin SP; Tucker LB; Rouster-Stevens KA; Witte D; Ying J; Devarajan P
J Rheumatol; 2017 Aug; 44(8):1239-1248. PubMed ID: 28620062
[TBL] [Abstract][Full Text] [Related]
25. TWEAK: a novel biomarker for lupus nephritis?
Dhaun N; Kluth DC
Arthritis Res Ther; 2009; 11(6):133. PubMed ID: 19951398
[TBL] [Abstract][Full Text] [Related]
26. Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis.
Costa-Reis P; Maurer K; Petri MA; Levy Erez D; Zhao X; Faig W; Burnham J; O'Neil K; Klein-Gitelman MS; von Scheven E; Schanberg LE; Sullivan KE
Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 35918102
[TBL] [Abstract][Full Text] [Related]
27. Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases.
Xuejing Z; Jiazhen T; Jun L; Xiangqing X; Shuguang Y; Fuyou L
J Biomed Biotechnol; 2012; 2012():359647. PubMed ID: 22719208
[TBL] [Abstract][Full Text] [Related]
28. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.
Schwartz N; Rubinstein T; Burkly LC; Collins CE; Blanco I; Su L; Hojaili B; Mackay M; Aranow C; Stohl W; Rovin BH; Michaelson JS; Putterman C
Arthritis Res Ther; 2009; 11(5):R143. PubMed ID: 19785730
[TBL] [Abstract][Full Text] [Related]
29. Lupus Nephritis.
Wenderfer SE; Eldin KW
Pediatr Clin North Am; 2019 Feb; 66(1):87-99. PubMed ID: 30454753
[TBL] [Abstract][Full Text] [Related]
30. Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis.
Adhya Z; El Anbari M; Anwar S; Mortimer A; Marr N; Karim MY
Lupus; 2019 May; 28(6):713-721. PubMed ID: 31046570
[TBL] [Abstract][Full Text] [Related]
31. Combined detection of uMCP-1 and uTWEAK for rapid discrimination of severe lupus nephritis.
Dong XW; Zheng ZH; Ding J; Luo X; Li ZQ; Li Y; Rong MY; Fu YL; Shi JH; Yu LC; Wu ZB; Zhu P
Lupus; 2018 May; 27(6):971-981. PubMed ID: 29451067
[TBL] [Abstract][Full Text] [Related]
32. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis.
Suzuki M; Wiers KM; Klein-Gitelman MS; Haines KA; Olson J; Onel KB; O'Neil K; Passo MH; Singer NG; Tucker L; Ying J; Devarajan P; Brunner HI
Pediatr Nephrol; 2008 Mar; 23(3):403-12. PubMed ID: 18202859
[TBL] [Abstract][Full Text] [Related]
33. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis.
El-Shehaby A; Darweesh H; El-Khatib M; Momtaz M; Marzouk S; El-Shaarawy N; Emad Y
J Clin Immunol; 2011 Oct; 31(5):848-56. PubMed ID: 21691937
[TBL] [Abstract][Full Text] [Related]
34. Urinary Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (uTWEAK) and Urinary Monocyte Chemo-attractant Protein-1 (uMCP-1): Promising Biomarkers of Lupus Nephritis Activity?
Elsaid DS; Abdel Noor RA; Shalaby KA; Haroun RA
Saudi J Kidney Dis Transpl; 2021; 32(1):19-29. PubMed ID: 34145111
[TBL] [Abstract][Full Text] [Related]
35. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.
Dall'Era M; Stone D; Levesque V; Cisternas M; Wofsy D
Arthritis Care Res (Hoboken); 2011 Mar; 63(3):351-7. PubMed ID: 21080348
[TBL] [Abstract][Full Text] [Related]
36. [Lupus nephritis].
Melderis S; Wiech T; Iking-Konert C; Steinmetz OM
Z Rheumatol; 2018 Sep; 77(7):593-608. PubMed ID: 29955955
[TBL] [Abstract][Full Text] [Related]
37. Successful Discontinuation of Glucocorticoid Treatment after Administration of a Calcineurin Inhibitor for Nephrotic Syndrome in a Patient with Lupus Nephritis.
Sawamura M; Sawa N; Ikuma D; Oba Y; Yamanouchi M; Sekine A; Mizuno H; Hasegawa E; Suwabe T; Hoshino J; Kono K; Kinowaki K; Ohashi K; Ubara Y
Intern Med; 2023 Apr; 62(7):1037-1041. PubMed ID: 36070938
[TBL] [Abstract][Full Text] [Related]
38. Comparison of lupus patients with early and late onset nephritis: a study in 71 patients from a single referral center.
Delfino J; Dos Santos TAFG; Skare TL
Adv Rheumatol; 2020 Jan; 60(1):5. PubMed ID: 31900216
[TBL] [Abstract][Full Text] [Related]
39. Urinary TWEAK and the activity of lupus nephritis.
Schwartz N; Su L; Burkly LC; Mackay M; Aranow C; Kollaros M; Michaelson JS; Rovin B; Putterman C
J Autoimmun; 2006 Dec; 27(4):242-50. PubMed ID: 17257812
[TBL] [Abstract][Full Text] [Related]
40. [Clinical implication of a novel biomarker Ngal in CKD].
Mori K; Mukoyama M; Kuwabara T; Kasahara M; Yokoi H; Nakao K
Nihon Rinsho; 2009 Jun; 67(6):1233-41. PubMed ID: 19507520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
